Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8486446 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 years from now) | |
US8741948 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 years from now) | |
US8263120 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 years from now) | |
US8529945 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(2 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 16, 2023 |
Generating Antibiotic Incentives Now (GAIN) | Nov 16, 2028 |
NCE-1 date: 2027-11-17
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE;ORAL
10
United States
3
European Union
2
Korea, Republic of
2
China
2
Japan
2
Canada
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Slovenia
1
Hungary
1
Germany
1
Croatia
1
Portugal
1
Cyprus
1
Spain
1
Italy
1
Poland
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic